Stonnington Group, LLC Bristol Myers Squibb CO Transaction History

Stonnington Group, LLC

$381 Million
Q1 2023

A detailed history of Stonnington Group, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Stonnington Group, LLC holds 35,845 shares of BMY stock, worth $2.26 Million. This represents 0.65% of its overall portfolio holdings.

Number of Shares

35,845

Previous 38,241 6.27%

Holding current value

$2.26 Million

Previous $2.75 Million 9.71%

% of portfolio

0.65%

Previous 0.77%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 14, 2023	SELL	$65.71 - $74.53 $157,441 - $178,573	-2,396 Reduced 6.27%	35,845 $2.48 Million
Q4 2022 Jan 11, 2023	SELL	$68.48 - $81.09 $287,410 - $340,334	-4,197 Reduced 9.89%	38,241 $0
Q3 2022 Oct 20, 2022	BUY	$0.13 - $76.84 $39 - $23,359	304 Added 0.72%	42,438 $3.02 Million
Q2 2022 Jul 08, 2022	BUY	$72.62 - $79.98 $256,203 - $282,169	3,528 Added 9.14%	42,134 $3.17 Million
Q1 2022 Apr 12, 2022	SELL	$61.48 - $73.72 $11.3 Million - $13.6 Million	-184,439 Reduced 82.69%	38,606 $2.95 Million
Q4 2021 Jan 12, 2022	SELL	$53.63 - $62.52 $212,374 - $247,579	-3,960 Reduced 11.05%	31,864 $2.09 Million
Q4 2021 Jan 12, 2022	BUY	$53.63 - $62.52 $10.3 Million - $12 Million	191,181 Added 599.99%	223,045 $14.6 Million
Q3 2021 Oct 12, 2021	SELL	$59.17 - $69.31 $210,645 - $246,743	-3,560 Reduced 9.04%	35,824 $2.05 Million
Q2 2021 Jul 09, 2021	BUY	$61.91 - $67.42 $191,921 - $209,002	3,100 Added 8.54%	39,384 $2.63 Million
Q1 2021 May 21, 2021	BUY	$59.34 - $66.74 $2.15 Million - $2.42 Million	36,284 New	36,284 $2.34 Million

Others Institutions Holding BMY

# of Institutions

2,761

Shares Held

1.57B

Call Options Held

28M

Put Options Held

28.7M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $134B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stonnington Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stonnington Group, LLC with notifications on news.

Account

Stonnington Group, LLC Bristol Myers Squibb CO Transaction History